| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/08/2000 | WO2000025754A3 Solid oral dosage forms containing alginic acid and famotidine |
| 09/08/2000 | WO2000023060A3 Method of treating immunological disorders mediated by t-lymphocytes |
| 09/08/2000 | WO2000019883A3 Compositions and methods of disease diagnosis and therapy |
| 09/08/2000 | WO2000019206A9 Ykl-40 as a marker and prognostic indicator for cancers |
| 09/08/2000 | WO2000018212A9 Platelet-derived growth factor c, dna coding therefor, and uses thereof |
| 09/08/2000 | WO2000013702A3 Use of an angiogenic factor for the treatment of microvascular angiopathies |
| 09/08/2000 | WO2000012702A3 Human genes differentially expressed in colorectal cancer |
| 09/08/2000 | WO2000010526A3 New oral formulation for 5-ht4 agonists or antagonists |
| 09/08/2000 | WO2000009709A3 Proteases and associated proteins |
| 09/08/2000 | WO2000000604A9 Methods and compositions for modulating spermatogenesis |
| 09/08/2000 | CA2364169A1 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease |
| 09/08/2000 | CA2364127A1 Composition comprising a tramadol material and a selective cox-2 inhibitor drug |
| 09/08/2000 | CA2363982A1 Pharmaceutical combination of antiviral agents |
| 09/08/2000 | CA2363961A1 Crystals and structural coordinate of protein complex and utilisation of the structural coordinate |
| 09/08/2000 | CA2363957A1 Immunomodulating glycopeptide |
| 09/08/2000 | CA2363488A1 Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities |
| 09/08/2000 | CA2363077A1 Methods for targeting rna molecules |
| 09/08/2000 | CA2362985A1 Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase |
| 09/08/2000 | CA2362840A1 Antibodies against phosphomannan that are protective against candidiasis |
| 09/08/2000 | CA2362501A1 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists |
| 09/08/2000 | CA2362488A1 Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists |
| 09/08/2000 | CA2362487A1 Compositions and methods for treatment of staphylococcal infection |
| 09/08/2000 | CA2362361A1 Bupropion metabolites and methods of their synthesis and use |
| 09/06/2000 | EP1033403A1 Gene originating in human fetal chondrocytes |
| 09/06/2000 | EP1032667A2 A33-related antigens and their pharmacological uses |
| 09/06/2000 | EP1032659A1 Grafted copolymers as gene carriers |
| 09/06/2000 | EP1032582A1 NOVEL recJ |
| 09/06/2000 | EP1032427A2 Conjugates of cytokines and drugs or genes for treating proliferating cells |
| 09/06/2000 | EP1032424A1 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor |
| 09/06/2000 | EP1032423A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof |
| 09/06/2000 | EP1032415A2 Composition for the treatment of allergic conditions having cysteine and serine proteinase inhibitory activity |
| 09/06/2000 | EP1032414A1 Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders |
| 09/06/2000 | EP1032405A1 Antimutagenic compositions for treatment and prevention of photodamage to skin |
| 09/06/2000 | EP1032403A1 Nutritional supplement for cerebral metabolic insufficiencies |
| 09/06/2000 | EP1032402A1 Citicoline to treat motor neuron diseases and demyelinating diseases |
| 09/06/2000 | EP1032397A1 Testosterone inhibitors and use for the protection of neurons |
| 09/06/2000 | EP0901379B1 Type-2 chemokine binding proteins and methods of use therefor |
| 09/06/2000 | EP0719145B1 Nitric oxide donor composition for treatment of anal disorders |
| 09/06/2000 | CN1265741A Method and compositions for overcoming resistance to biologic and chemotherapy |
| 09/06/2000 | CN1265672A Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265657A Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265648A Conjugaes of dithiocarbamates with pharmacologically active agents and uses therefor |
| 09/06/2000 | CN1265598A Method for treating thrombotic disorders |
| 09/06/2000 | CN1056145C Prepn. of 1,3-oxathiolane nucleoside analogue medicine composition |
| 09/06/2000 | CN1056083C Method and compositions for treatment and repair of defects or lesions in cartilage |
| 09/05/2000 | US6114517 Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules |
| 09/05/2000 | US6114515 PIGRL-1, a member of immunoglobulin gene superfamily |
| 09/05/2000 | US6114506 Composition and method for enhancing fibrinolysis |
| 09/05/2000 | US6114393 Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa |
| 09/05/2000 | US6114385 Administering l-carnitine, acyl l-carnitine derivatives or pharmacologically acceptable salts thereof for prophylaxis of diseases or treatment of cellular disorders caused by high levels of ceramide |
| 09/05/2000 | US6114376 Reversing agent is ll-f28249alpha-lambda series of compounds, the 23-oxo or 23-imino derivative thereof, the avermectins, the 22,23-dihydro derivatives thereof and the milbemycins |
| 09/05/2000 | US6114347 Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors |
| 09/05/2000 | US6114346 Treating sleep disorders using desloratadine |
| 09/05/2000 | US6114328 Isoxazoline and isoxazole fibrogen receptor antagonists |
| 09/05/2000 | US6114326 Sleep disorders |
| 09/05/2000 | US6114320 Therapeutic treatment for VEGF related ocular diseases |
| 09/05/2000 | US6114304 Administering an amylin agonist such as pramlintide or pramlintide acetate; reducing gastric motility or delaying gastric emptying |
| 09/05/2000 | US6113920 Pharmaceutical compositions |
| 09/05/2000 | US6113906 Water-soluble non-antigenic polymer linkable to biologically active material |
| 09/05/2000 | US6113899 Antagonists of chaperonin 10 |
| 09/05/2000 | US6113879 Isolated d-threo-methylphenidate enantiomorph; attention deficit-hyperactivity disorder; nontoxic |
| 09/05/2000 | US6113629 Hydrogel for the therapeutic treatment of aneurysms |
| 09/05/2000 | CA2188662C New method of treatment |
| 08/31/2000 | WO2000050639A2 Gene sequence variations with utility in determining the treatment of disease |
| 08/31/2000 | WO2000050590A1 Mdm interacting protein and methods of use thereof |
| 08/31/2000 | WO2000050565A2 Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene |
| 08/31/2000 | WO2000050562A2 Dna encoding snorf25 receptor |
| 08/31/2000 | WO2000050460A1 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses |
| 08/31/2000 | WO2000050453A1 A novel inhibitor of programmed cell death |
| 08/31/2000 | WO2000050445A1 Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase |
| 08/31/2000 | WO2000050386A1 Compounds and compositions for delivering active agents |
| 08/31/2000 | WO2000050095A1 Bioadhesive antibacterial wound healing composition |
| 08/31/2000 | WO2000050082A1 Combination therapy for lymphoproliferative diseases |
| 08/31/2000 | WO2000050046A1 Stabilized oral pharmaceutical composition containing iodide and iodate and method |
| 08/31/2000 | WO2000050043A1 Methods of treatment of mitochondrial disorders |
| 08/31/2000 | WO2000050037A1 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use |
| 08/31/2000 | WO2000050034A1 Gaba receptors mediate inhibition of t cell responses |
| 08/31/2000 | WO2000050033A2 Anti-tumor synergetic composition |
| 08/31/2000 | WO2000050032A1 Antitumour synergistic composition |
| 08/31/2000 | WO2000050022A2 Treatment regimen for hormone-sensitive cancers |
| 08/31/2000 | WO2000050021A2 Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started |
| 08/31/2000 | WO2000049993A2 Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
| 08/31/2000 | WO2000049937A2 Trpm-2 antisense therapy |
| 08/31/2000 | WO2000049896A1 Dietary compositions and methods |
| 08/31/2000 | WO2000028029A3 Cell surface glycoproteins |
| 08/31/2000 | WO2000027849A3 Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| 08/31/2000 | WO2000027382A3 Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e |
| 08/31/2000 | WO2000027196A8 Use of gm-csf to inhibit development of drug resistance in hiv+ patients |
| 08/31/2000 | WO2000026236A3 Method of modulating cell differentiation or neoplastic transformation by altering cadherin-11 expression or function |
| 08/31/2000 | WO2000025805A8 Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2 |
| 08/31/2000 | WO2000023112A9 Modulation of gene expression by combination therapy |
| 08/31/2000 | WO2000019823A9 Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof |
| 08/31/2000 | WO2000019200A9 Identifying agents that alter mitochondrial permeability transition pores |
| 08/31/2000 | WO2000018923A9 Slgp protein and nucleic acid molecule and uses therefor |
| 08/31/2000 | WO2000012074A3 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| 08/31/2000 | CA2850318A1 Trpm-2 antisense therapy |
| 08/31/2000 | CA2371814A1 Trpm-2 antisense therapy |
| 08/31/2000 | CA2366697A1 Treatment regimen for hormone-sensitive cancers |
| 08/31/2000 | CA2364849A1 Compounds and compositions for delivering active agents |
| 08/31/2000 | CA2363637A1 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses |